Muscarinic receptor subtypes in hippocampus in Alzheimer's disease and mixed dementia type.
Central vascular disease and exacerbated pathology in a mixed model of type 2 diabetes and Alzheimer's disease.
[A case report of mixed type dementia combining Binswanger's disease with senile dementia of Alzheimer's type].
Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial.
Koychev I, Reid G, Nguyen M, Mentz RJ, Joyce D, Shah SH, Holman RR.
Alzheimers Res Ther. 2024 Oct 2;16(1):212. doi: 10.1186/s13195-024-01573-x.
gamma-Secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS).
Schultz SA, Liu L, Schultz AP, Fitzpatrick CD, Levin R, Bellier JP, Shirzadi Z, Joseph-Mathurin N, Chen CD, Benzinger TLS, Day GS, Farlow MR, Gordon BA, Hassenstab JJ, Jack CR Jr, Jucker M, Karch CM, Lee JH, Levin J, Perrin RJ, Schofield PR, Xiong C, Johnson KA, McDade E, Bateman RJ, Sperling RA, Selkoe DJ, Chhatwal JP; Dominantly Inherited Alzheimer Network.
Lancet Neurol. 2024 Sep;23(9):913-924. doi: 10.1016/S1474-4422(24)00236-9. Epub 2024 Jul 26.
Timing of Alzheimer's Disease by Intellectual Disability Level in Down Syndrome.
Hartley SL, Fleming V, Schworer EK, Peven J, Handen BL, Krinsky-McHale S, Hom C, Lee L, Tudorascu DL, Laymon C, Minhas D, Luo W, Cohen A, Zaman S, Ances BM, Mapstone M, Head E, Lai F, Rosas HD, Klunk W, Christian B; Alzheimer Biomarker Consortium-Down Syndrome.
J Alzheimers Dis. 2023;95(1):213-225. doi: 10.3233/JAD-230200.
Analysis of early effects of human APOE isoforms on Alzheimer's disease and type III hyperlipoproteinemia pathways using knock-in rat models with humanized APP and APOE.
Yesiltepe M, Yin T, Tambini M, Bao H, Pan M, d'Abramo C, Giliberto L, Han X, D'Adamio L.
Cell Commun Signal. 2024 Sep 27;22(1):458. doi: 10.1186/s12964-024-01832-2.
Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes.
Hierro-Bujalance C, Infante-Garcia C, Del Marco A, Herrera M, Carranza-Naval MJ, Suarez J, Alves-Martinez P, Lubian-Lopez S, Garcia-Alloza M.
Alzheimers Res Ther. 2020 Apr 7;12(1):40. doi: 10.1186/s13195-020-00607-4.
Repurposing antidiabetic drugs for Alzheimer's disease: A review of preclinical and clinical evidence and overcoming challenges.
Tran J, Parekh S, Rockcole J, Wilson D, Parmar MS.
Life Sci. 2024 Oct 15;355:123001. doi: 10.1016/j.lfs.2024.123001. Epub 2024 Aug 21.
Cofilin promotes tau pathology in Alzheimer's disease.
Yan M, Tang L, Dai L, Lei C, Xiong M, Zhang X, He M, Tian Y, Xiong J, Ke W, Zhang Z, Zhang C, Deng X, Zhang Z.
Cell Rep. 2023 Feb 28;42(2):112138. doi: 10.1016/j.celrep.2023.112138. Epub 2023 Feb 17.
The autophagy adaptor TRIAD3A promotes tau fibrillation by nested phase separation.
Zhou J, Chuang Y', Redding-Ochoa J, Zhang R, Platero AJ, Barrett AH, Troncoso JC, Worley PF, Zhang W.
Nat Cell Biol. 2024 Aug;26(8):1274-1286. doi: 10.1038/s41556-024-01461-4. Epub 2024 Jul 15.
Association of ten VEGF family genes with Alzheimer's disease endophenotypes at single cell resolution.
Wu Y, Libby JB, Dumitrescu L, De Jager PL, Menon V, Schneider JA, Bennett DA, Hohman TJ.
Alzheimers Dement. 2025 Feb;21(2):e14419. doi: 10.1002/alz.14419. Epub 2024 Dec 6.
Cardiovascular risk factors of Alzheimer's disease and other neurocognitive disorders in Malaysia.
Ibrahim B, Suppiah S, Piersson AD, Razali RM, Mohamad M, Abu Hassan H, Ibrahim N.
Med J Malaysia. 2021 May;76(3):291-297.
